ABBV Stock Recent News
ABBV LATEST HEADLINES
The Investment Committee give you their top stocks to watch for the second half.
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.
Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill. , May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer through a campaign called "Striking Out Cancer" which starts today when the Chicago Cubs play the Cincinnati Reds.
NEW YORK , May 30, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud.
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
Money market funds are booming with $7.2 trillion in assets, offering attractive short-term yields, but rising fees and competition could shake things up. I believe we're nearing a turning point: lower rates may push massive capital into dividend stocks, boosting prices and driving down future yields. In the second half of the article, I highlight three high-quality dividend stocks I believe could significantly benefit from this money market rotation trend.
NEW YORK , May 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.